Cargando…

Emergence and Persistence of Letermovir-Resistant Cytomegalovirus in a Patient With Primary Immunodeficiency

BACKGROUND: Letermovir is a novel cytomegalovirus antiviral that is approved for prophylaxis in hematopoietic stem cell transplantation recipients METHODS: After obtaining informed consent, letermovir prophylaxis was started in a patient with a presumed late-onset primary, combined T- and B-cell imm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Popping, Stephanie, Dalm, Virgil A S H, Lübke, Nadine, Cristanziano, Veronica di, Kaiser, Rolf, Boucher, Charles A B, Van Kampen, Jeroen J A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6763208/ https://www.ncbi.nlm.nih.gov/pubmed/31660414 http://dx.doi.org/10.1093/ofid/ofz375

Ejemplares similares

Letermovir for cytomegalovirus prophylaxis
Publicado: (2019)

Clinical and In Vitro Evidence Favoring Immunoglobulin Treatment of a Chronic Norovirus Infection in a Patient With Common Variable Immunodeficiency
por: van Kampen, Jeroen J A, et al.
Publicado: (2022)

Letermovir for the compassionate therapeutic use of cytomegalovirus infection
por: Schubert, Lorenz, et al.
Publicado: (2020)

Real-World Outcomes Associated With Letermovir Use for Cytomegalovirus Primary Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients: A Systematic Review and Meta-analysis of Observational Studies
por: Vyas, Ami, et al.
Publicado: (2022)

2648. Terminating the Troll of Transplantation: Letermovir for Cytomegalovirus Prophylaxis
por: Hedvat, Jason, et al.
Publicado: (2019)

Letermovir for Cytomegalovirus Prevention in Patients Undergoing Hematopoietic Cell Transplantation
por: Daniels, Kori, et al.
Publicado: (2019)

In vitro assessment of the combined effect of letermovir and sirolimus on cytomegalovirus replication
por: Giménez, Estela, et al.
Publicado: (2023)

Combined Therapy with Intravenous Immunoglobulins, Letermovir and (Val-)Ganciclovir in Complicated Courses of CMV-Infection in Transplant Recipients
por: Di Cristanziano, Veronica, et al.
Publicado: (2021)

2740. Letermovir for the Prevention and Treatment of Cytomegalovirus Infection in Solid Organ Transplant Recipients
por: Xhemali, Xhilda, et al.
Publicado: (2023)

Cytomegalovirus Retinitis Screening and Treatment in Human Immunodeficiency Virus Patients in Malawi: A Feasibility Study
por: Ocieczek, Paulina, et al.
Publicado: (2019)

Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review
por: El Helou, Guy, et al.
Publicado: (2019)

Extended-duration letermovir prophylaxis for cytomegalovirus infection after cord blood transplantation in adults
por: Politikos, Ioannis, et al.
Publicado: (2022)

Ganciclovir/letermovir: Rebound Cytomegalovirus hepatitis, acquired resistance to ganciclovir and nephrotoxicity: case report
Publicado: (2020)

571. “Real world” Impact of Letermovir for Prevention of Cytomegalovirus Infection in Hematopoietic-Cell Transplantation
por: Loecher, Alyssa M, et al.
Publicado: (2020)

Assessment of UL56 Mutations before Letermovir Therapy in Refractory Cytomegalovirus Transplant Recipients
por: Santos Bravo, Marta, et al.
Publicado: (2022)

Letermovir for Prophylaxis and Pre-emptive Therapy of Cytomegalovirus Infection in Paediatric Allogeneic Haematopoietic Cell Transplant Patients
por: Körholz, Katharina F., et al.
Publicado: (2022)

Letermovir Prophylaxis for Cytomegalovirus Infection in Allogeneic Stem Cell Transplantation: A Real-World Experience
por: Martino, Massimo, et al.
Publicado: (2021)

Letermovir and its role in the prevention of cytomegalovirus infection in seropositive patients receiving an allogeneic hematopoietic cell transplant
por: Shigle, Terri Lynn, et al.
Publicado: (2020)

A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation
por: Ljungman, Per, et al.
Publicado: (2020)

Persistence of Human Immunodeficiency Virus-1 Drug Resistance Mutations in Proviral Deoxyribonucleic Acid After Virologic Failure of Efavirenz-Containing Antiretroviral Regimens
por: De La Cruz, Justin, et al.
Publicado: (2019)

Impact of Obefazimod on Viral Persistence, Inflammation, and Immune Activation in People With Human Immunodeficiency Virus on Suppressive Antiretroviral Therapy
por: Bernal, Silvia, et al.
Publicado: (2023)

Clinical Characteristics and Outcomes of Immunocompromised Patients With Coronavirus Disease 2019 Caused by the Omicron Variant: A Prospective, Observational Study
por: Malahe, S Reshwan K, et al.
Publicado: (2022)

Emergence of Human Immunodeficiency Virus-1 Drug Resistance During the 3-Month World Health Organization-Recommended Enhanced Adherence Counseling Period in the CART-1 Cohort Study
por: Brown, Jennifer A, et al.
Publicado: (2021)

Cost-effectiveness analysis of the use of letermovir for the prophylaxis of cytomegalovirus in adult cytomegalovirus seropositive recipients undergoing allogenic hematopoietic stem cell transplantation in Italy
por: Restelli, Umberto, et al.
Publicado: (2019)

Letermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirus
por: Melendez, Dante P, et al.
Publicado: (2015)

Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient
por: Jung, Susanne, et al.
Publicado: (2019)

928. Concordance with Institutional Guidelines for Letermovir Cytomegalovirus Infection Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients
por: Peterson-Weber, Alex, et al.
Publicado: (2023)

Multidisciplinary Approach to Improve Human Immunodeficiency Virus and Syphilis Testing Rates in Emergency Departments
por: Erickson, Jessica L, et al.
Publicado: (2022)

Association of Cytomegalovirus DNA and Immunologic Markers of Cardiovascular Disease
por: Garg, Ankita, et al.
Publicado: (2019)

Targeted HCV core antigen monitoring among HIV-positive men who have sex with men is cost-saving
por: Popping, Stephanie, et al.
Publicado: (2019)

In Vivo Emergence of UL56 C325Y Cytomegalovirus Resistance to Letermovir in a Patient with Acute Myeloid Leukemia after Hematopoietic Cell Transplantation
por: Frietsch, Jochen J, et al.
Publicado: (2019)

Advanced Human Immunodeficiency Virus Disease at Diagnosis in Mozambique and Swaziland
por: Kujawski, Stephanie A, et al.
Publicado: (2017)

Predictors of breakthrough clinically significant cytomegalovirus infection during letermovir prophylaxis in high‐risk hematopoietic cell transplant recipients
por: Royston, Léna, et al.
Publicado: (2021)

Letermovir Prophylaxis and Cytomegalovirus Reactivation in Adult Hematopoietic Cell Transplant Recipients with and without Acute Graft Versus Host Disease
por: Wolfe, Delaney, et al.
Publicado: (2021)

1995. Duration of letermovir primary prophylaxis in hematopoietic cell transplant recipients at high risk for cytomegalovirus infections and impact on outcomes
por: Febres-Aldana, Anthony J, et al.
Publicado: (2023)

926. Risk factors for post-letermovir cytomegalovirus (CMV) reactivation in allogeneic hematopoietic stem cell transplant (HSCT) recipients
por: Mendoza, Maria Alejandra, et al.
Publicado: (2023)

Cost Effectiveness of Letermovir for Cytomegalovirus Prophylaxis Compared with Pre-Emptive Therapy in Allogeneic Hematopoietic Stem Cell Transplant Recipients in the United States
por: Sepassi, Aryana, et al.
Publicado: (2023)

A Mortality Analysis of the Cytomegalovirus (CMV) Infection Letermovir Prophylaxis Trial in CMV-Seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation (HCT)
por: Maertens, Johan, et al.
Publicado: (2017)

A Prospective Study of Cytomegalovirus-Specific Cell-Mediated Immune Monitoring and Cytomegalovirus Infection in Patients With Active Systemic Lupus Erythematosus Receiving Immunosuppressants
por: Bruminhent, Jackrapong, et al.
Publicado: (2021)

Multiple-Strain Infections of Human Cytomegalovirus With High Genomic Diversity Are Common in Breast Milk From Human Immunodeficiency Virus–Infected Women in Zambia
por: Suárez, Nicolás M, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_n3pfsoorfu29c6a5fd68gfjmhf